AIDS/HIV PROBLEM Clinical Trial
Official title:
Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection
This study is a prospective trial which will recruit 18 patients in acute HIV-1 infection phase. This study aims to evaluate the effects and side effects of ARV treatment in Chinese patients in acute HIV-1 infection phase, and to evaluate the impact of Triptolide wilfordii on HIV-1 reservoir.
Two arms will be enrolled in this study, 18 naive-treatment Chinese patients in acute HIV-1 infection phase would be allocated to two arms, and treated with the antiretroviral drugs (Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir). Six months later, 12 patients will be treated with Triplitode, in order to observe the impact of of Triptolide wilfordii on HIV-1 reservoir of patients in acute infection phase. All patients should be explored for 18 months in terms of the clinical features, drugs side-effects, and immunological and viral response, and the HIV-1 reservoir. We hypothesis that Triptolide wilfordii might further reduce the HIV-1 reservoir. The result would provide proofs for further practical antiviral therapy for patients in acute infection phase in China or other resource limited countries. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04653441 -
Resilience-based Psychosocial Intervention Among Children Affected by HIV/AIDS
|
N/A | |
Completed |
NCT01507142 -
Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients
|
N/A | |
Not yet recruiting |
NCT01844297 -
Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy
|
N/A | |
Not yet recruiting |
NCT01844310 -
Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection
|
N/A | |
Completed |
NCT05065905 -
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04144335 -
N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01589965 -
The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence in Lesotho
|
Phase 0 |